Phase III clinical trial of China's covid-19 inactivated vaccine launched in Argentina

2020-08-24
|
ChinaMedical

The world’s first inactivated COVID-19 vaccine developed and produced by Sinopharm Group’s China National Biotec Group (CNBG) was approved by the National Food, Drugs and Medical Technology Administration (ANMAT) under the Ministry of Health of Argentina on August 13 for trial test.


China will cooperate with ELEA in Argentina to promote the international clinical trials (phase III) of the above vaccine in Argentina.


At the launching ceremony, representatives of the Argentine government issued a clinical trial approval certificate for the covid-19 inactivated vaccine to Sinopharm Group China Biotech (CNBG).


RELATED ARTICLES

Memoray completes tens of millions of yuan in Series B financing
2020-11-18
|
PEVC , Medical care

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

Orthopedic AI company Changmugu closes Series A+ of RMB tens of mlns
2020-09-12
|
PEVC , Medical care

Lu Daopei Medical closes Series B+ exceeding RMB 100 mln
2020-09-11
|
PEVC , Medical care

JD.com reaches strategic cooperation with Tongrentang Health
2020-09-09
|
Medical care , PEVC

China started emergency use of Covid-19 vaccine on July 22
2020-08-23
|
Covid-19 , Medical care , Vaccine

First international Phase III clinical trial of Covid-19 vaccine launched
2020-06-23
|
Healthcare , Pharmaceutical

First coronavirus vaccine clinical result unveiled: 100% antibody coversion in 28 days
2020-06-16
|
Coronavirus , Medical care
China SDG